NYSE:MNK - Mallinckrodt Stock Price, Forecast & News

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

Mallinckrodt PLC (NYSE:MNK) issued its earnings results on Tuesday, November, 5th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. The company earned $743.70 million during the quarter, compared to analyst estimates of $770.56 million. Mallinckrodt had a positive return on equity of 24.36% and a negative net margin of 111.44%. The business's revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.10 EPS. View Mallinckrodt's Earnings History.

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Mallinckrodt.

14 brokerages have issued 12-month price objectives for Mallinckrodt's stock. Their forecasts range from $2.00 to $22.00. On average, they expect Mallinckrodt's stock price to reach $8.64 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price. View Analyst Price Targets for Mallinckrodt.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.

Media headlines about MNK stock have trended positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mallinckrodt earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Mallinckrodt.

Mallinckrodt saw a decrease in short interest in December. As of December 13th, there was short interest totalling 46,160,000 shares, a decrease of 9.4% from the November 28th total of 50,930,000 shares. Based on an average trading volume of 7,250,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 55.7% of the shares of the company are sold short. View Mallinckrodt's Current Options Chain.

Some companies that are related to Mallinckrodt include Forty Seven (FTSV), Zymeworks (ZYME), Arvinas (ARVN), Tricida (TCDA), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Alder Biopharmaceuticals (ALDR), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA) and Theravance Biopharma (TBPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Micron Technology (MU), Gilead Sciences (GILD), Bausch Health Companies (BHC), Gerdau (GGB), Teva Pharmaceutical Industries (TEVA), Celgene (CELG), Endo International (ENDP), Skyworks Solutions (SWKS), Alibaba Group (BABA) and AT&T (T).

Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional investors include Clear Creek Financial Management LLC (0.03%), Beirne Wealth Consulting Services LLC (0.03%) and Commerzbank Aktiengesellschaft FI (0.02%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, James E Flynn and Mark Trudeau. View Institutional Ownership Trends for Mallinckrodt.

MNK stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI and Clear Creek Financial Management LLC. View Insider Buying and Selling for Mallinckrodt.

MNK stock was purchased by a variety of institutional investors in the last quarter, including Beirne Wealth Consulting Services LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons and Mark Trudeau. View Insider Buying and Selling for Mallinckrodt.

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNK stock can currently be purchased for approximately $5.20.

Mallinckrodt has a market capitalization of $437.27 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.

The official website for Mallinckrodt is http://www.mallinckrodt.com/.

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]